CSL Limited (CSLLY)
(Delayed Data from OTC)
$105.63 USD
+2.27 (2.20%)
Updated Aug 23, 2024 03:51 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
CSL Limited Sponsored ADR (CSLLY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$110.00 | $110.00 | $110.00 | 6.42% |
Price Target
Only one analyst offered a short-term price target of $110.00 for CSL Limited Sponsored ADR. This represents an increase of 6.42% from the last closing price of $103.36.
Analyst Price Targets (1 )
Broker Rating
CSL Limited Sponsored ADR currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.57 a month ago based on seven recommendations.
Of the eight recommendations deriving the current ABR, six are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 71.43%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/CSLLY.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.57 | 1.57 | 1.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/14/2024 | Not Identified | Not Identified | Hold | Hold |
8/13/2024 | Macquarie Capital Securities | David Bailey | Not Available | Strong Buy |
2/20/2024 | UBS | Laura Sutcliffe | Strong Buy | Strong Buy |
2/14/2024 | Not Identified | Not Identified | Not Available | Hold |
11/14/2023 | Goldman Sachs | Chris Cooper | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 8 |
Average Target Price | $110.00 |
LT Growth Rate | 14.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | NA |